Role of curcumin curcumin (NCB02) enemas in treating ulcerative colitis

INTERVENTION: Intervention1: Curcumin (NCB02): Each curcumin enema contained 140 mg of curcumin dissolved in 20 ml of water. Patients were advised to take the enema preparation in the night prior to sleep. All the patients, in addition to trail drug, received oral mesalamine in a dosage of 800 mg twice daily for 8 weeks Control Intervention1: Placebo: oral mesalamine in a dosage of 800 mg twice daily and placebo for 8 weeks CONDITION: Active distal ulcerative colitis PRIMARY OUTCOME: The primary outcome measure was improvement in activity of UC. This was defined as a decrease in the UCDAI by equal or more than 3 from baseline‐‐‐‐‐‐Timepoint: 8 weeks SECONDARY OUTCOME: Secondary outcome measures were proportion of patients achieving remission and mucosal healing‐‐‐‐‐‐Timepoint: 8 week INCLUSION CRITERIA: 1. Adult patients 2. Mild‐to‐moderately active proctitis and proctosigmoiditis (Ulcerative Colitis Disease Activity Index [UCDAI] score, 3‐9), with endoscopic disease extent up to 25 cm from the anal verge 3. Patients receiving mesalamine if the dose is stable for more than 8 weeks